CD274 and non-small cell lung carcinoma: It started with the national reimbursement of pembrolizumab for stage IV, PD-L1 positive NSCLC patients in 2L in September 2016 (23), whereas the most recent immune checkpoint inhibitor reimbursement approval for NSCLC came in October 2021, with pembrolizumab for stage IV, 1L for squamous carcinoma NSCLC patients with low PD-L1 expression (24).